Group 1 - The core viewpoint of the news is the performance and holdings of the Industrial and Commercial Bank of China Medical Healthcare Stock Fund, which has shown positive returns in recent months and has a diversified portfolio in the healthcare sector [1][3] - As of May 9, 2025, the latest net value of the fund is 2.5040 yuan, with a growth of 0.72%. The fund's return over the past month is 5.17%, ranking 504 out of 783 in its category; over the past three months, the return is 9.06%, ranking 88 out of 778; and year-to-date, the return is 9.87%, ranking 103 out of 773 [1] - The top ten holdings of the fund account for a total of 39.79%, with significant investments in companies such as Heng Rui Pharmaceutical (8.90%), WuXi AppTec (5.12%), and Mindray Medical (2.80%) [1] Group 2 - The fund was established on November 18, 2014, and as of March 31, 2025, it has a total scale of 2.724 billion yuan. The fund managers are Zhao Bei and Ding Yang [1] - Zhao Bei has extensive experience in the healthcare sector, having served as the fund manager for various healthcare-related funds since 2014, while Ding Yang joined the company in 2017 and currently serves as a fund manager [2]

随着行情逐步企稳抬头，部分近期成立的次新基金已经"迫不及待"地布局A股市场，多只产品已有不同程 度的净值变化，更有基金成立半个月就将股票仓位买至九成。 值得一提的是，相较于红利或高股息产品，在震荡市中更为"自信"的次新基金多数为科技主题类产品，有基金 经理认为，与前两年的观望态度完全不同，AI行业的推动速度随时有可能迎来奇点，当前相关行业进展已按 下加速键，具备长期向好的投资逻辑。 部分次新基金大胆"试水" 以4月1日成立的太平科技先锋为例，在成立的次日净值即开始了波动，而在4月3日更是下跌1.21%，伴随行情 的回暖，该基金在短暂下跌后迅速拉升，不到一个月涨幅已有2.62%。 比如，成立于今年3月14日成立的德邦高端装备，截至一季度末重仓了包括绿的谐波、浙江荣泰、兆威机电等 人形机器人个股，囿于行情的走低，该基金一个多月以来跌幅超过了9%。 也有个别产品布局较为谨慎，如华宝远识在截至一季度末股票仓位为0，因此下跌行情里保持了平稳的走势。 基金经理写道：新的技术发展方向虽已出现，但距离系统性的业绩确认尚有一段路要走，指数估值需要等待业 绩兑现后的消化。中证红利指数市盈率7.28倍，市净率0.75倍，股息率所提 ...

Investment Rating - The industry investment rating is "stronger than the market" indicating an expected performance that exceeds the market by more than 5% over the next six months [49]. Core Views - The chemical agents and blood products sectors are expected to perform outstandingly in 2024, with positive revenue and profit growth reported in the CXO and medical services (hospitals) sectors for Q1 2025 [4][5]. - The biopharmaceutical industry is anticipated to outperform the market overall [4]. Summary by Sections Industry Performance - As of April 30, 2025, 467 A-share biopharmaceutical companies reported their 2024 annual and Q1 2025 results. In 2024, 28 companies had revenue growth exceeding 30%, while 50 companies exceeded 20%, and 113 companies exceeded 10%. Approximately 220 companies reported positive revenue growth, while 246 experienced negative growth. On the profit side, 102 companies had profit growth over 30%, 132 over 20%, and 172 over 10%, with 218 maintaining positive profit growth and 249 facing negative growth [4]. - In Q1 2025, 24 companies reported revenue growth over 30%, 52 over 20%, and 109 over 10%, with 214 maintaining positive revenue growth and 251 reporting negative growth. For profits, 100 companies had growth over 30%, 120 over 20%, and 159 over 10%, with 220 maintaining positive profit growth and 240 facing negative growth [4]. Investment Strategies - Focus on "innovation," "going global," "equipment upgrades," and "consumption recovery." - **Innovation**: Invest in globally competitive innovative drugs and categories with significant market potential. Recommended companies include BeiGene, Dongcheng Pharmaceutical, and others [7]. - **Going Global**: Explore overseas markets for long-term opportunities, with companies like Mindray Medical and others highlighted [7]. - **Equipment Upgrades**: Expect support for medical equipment updates from central and local government financing, with companies like Mindray Medical and others recommended [7]. - **Consumption Recovery**: Anticipate recovery in quality sectors like ophthalmology and medical aesthetics, with companies such as Puri Eye Hospital and others suggested [7]. Key Companies to Watch - **Nocare Biopharma**: Expected to achieve over 1 billion yuan in revenue from its core product, with a 49% year-on-year sales increase. The company reported a gross margin of 86.3% and a significant reduction in losses [8]. - **Sihuan Pharmaceutical**: Strong fundamentals with core products maintaining growth, and a robust pipeline expected to yield multiple approvals from 2025 to 2027 [11]. - **China Biopharmaceutical**: Rapid revenue growth with an increasing share of innovative products, and a strong pipeline in oncology [13]. - **Aibo Medical**: Anticipated growth in high-end artificial lenses and recovery in consumption due to aging trends [23]. Industry News Highlights - BeiGene's Sonrotoclax NDA application has been accepted for review, indicating potential market entry for a new treatment for CLL/SLL [30]. - Novartis' Pluvicto has received acceptance for a new indication in China, expanding its market potential [31]. - The partnership between Fuhong Hanlin and Sandoz for HLX13 indicates a significant milestone in the commercialization of biosimilars [33].

Investment Rating - The industry investment rating is "stronger than the market" indicating an expected performance that exceeds the market by more than 5% over the next six months [50]. Core Insights - The chemical agents and blood products sectors showed outstanding performance in 2024, while the CXO and medical services (hospitals) sectors reported positive growth in both revenue and profit for Q1 2025 [4][5]. - As of April 30, 2025, among 467 selected A-share biopharmaceutical companies, 28 companies reported revenue growth exceeding 30% for 2024, while 50 companies had growth over 20% [4]. - In Q1 2025, 24 companies achieved revenue growth greater than 30%, and 100 companies reported profit growth exceeding 30% [4]. Summary by Sections Industry Performance - In 2024, the chemical agents and blood products sectors maintained positive growth in both revenue and profit [5]. - For Q1 2025, the CXO and medical services sectors also reported positive growth in revenue and profit [5]. Investment Strategy - Focus on "innovation," "going global," "equipment upgrades," and "consumption recovery" as key investment themes [7]. - Recommended companies for "innovation" include BeiGene, Dongcheng Pharmaceutical, and others [7]. - For "going global," companies like Mindray Medical and Sinopharm are highlighted [7]. - In "equipment upgrades," companies such as Mindray Medical and Aohua Medical are suggested [7]. - Under "consumption recovery," companies like Puri Eye Hospital and Tongce Medical are noted [7]. Key Companies to Watch - **Nocera Health**: Achieved revenue of 1.009 billion yuan in 2024, with a 49% year-on-year increase in sales of its core product, Obinutuzumab [8]. - **Sihuan Pharmaceutical**: Maintained a stable performance with core products continuing to grow [11]. - **China Biopharmaceutical**: Rapid revenue growth with an increasing proportion of innovative products expected to accelerate profit growth [13]. - **Aibao Medical**: The launch of its self-developed ICL lens is expected to drive significant revenue growth [23]. Industry News Highlights - BeiGene's Sonrotoclax new drug application has been accepted for review [30]. - Novartis' Lutetium-177 injection has been accepted for a new indication in China [31]. - Fuhong Hanlin signed a licensing agreement with Sandoz for HLX13 [33]. - BeiGene won a patent dispute, strengthening its market position for its BTK inhibitor [34].

"如果再出现这样的机会，我会在一秒钟内做出反应，以低于市场平均市盈率水平的价格，一篮子的买 入一批大型制药股。" 对于医药股，股神巴菲特很坦诚，因为他很难去做选择，所以错过了一大批投资机会。5月3日，在今年 的股东大会上，巴菲特对于医药股更是鲜有提及。 不过，股神没有青睐的行业，并不是说没有机会。就在今年以来，A股、港股的医药板块悄然崛起，目 前累计涨幅已经超过火爆的机器人板块，而创新药板块更是成为这波上涨的"急先锋"。 来自WIND资讯的统计数据显示，截至4月30日，在港股上市的恒生生物科技指数(HSHKBIO)今年以来 表现突出，同期累计涨幅达到32.83%,而同期恒生科技指数的涨幅仅有17.37%。 更为引人关注的是，这波行情已经蔓延到医药股，就连A股相关主题基金也受益匪浅，多只医药主题基 金今年以来涨幅已经超过40%。 (1)看点一：业绩领跑 如果说今年表现最火的板块，那大多数人的第一反应，肯定是科技板块，尤其是机器人板块。不过，现 在又有了新变化。 上述统计显示，就在港股板块中，随着生物科技指数的大涨，一个不容忽视的事实是，主要投资医药尤 其是创新药板块的生物科技指数，已经大幅跑赢了恒生科技指数，而 ...

Group 1 - The core point of the article highlights the performance and holdings of the Ping An Medical Health Mixed C fund, which has a latest net value of 2.0423 yuan, down by 4.04% [1] - The fund has shown a monthly return of 13.52%, ranking 1343 out of 4649 in its category, a three-month return of 29.39%, ranking 27 out of 4597, and a year-to-date return of 31.91%, ranking 40 out of 4556 [1] - The top ten stock holdings of the fund account for a total of 83.49%, with significant positions in companies such as Kangfang Biotech (9.32%), BeiGene-U (9.13%), and others [1] Group 2 - The Ping An Medical Health Mixed C fund was established on November 28, 2023, and as of March 31, 2025, it has a total scale of 1.339 billion yuan [1] - The fund manager, Zhou Sicong, has a background in finance with experience at various fund management companies, including roles as a research analyst and fund manager [2]

金融界2025年5月7日消息，汇添富医疗服务灵活配置混合A(001417) 最新净值1.5080元，下跌2.27%。该 基金近1个月收益率10.88%，同类排名84|2324；近3个月收益率27.91%，同类排名5|2317；今年来收益 率25.25%，同类排名17|2306。 简历显示：张韡女士:中国。康奈尔大学生物医学硕士,曾任东方证券医药助理研究员,汇添富基金医药研 究员、高级医药研究员及医药行业研究组组长。2021年9月29日起任汇添富香港优势精选混合型证券投 资基金基金经理。2022年10月21日担任汇添富达欣灵活配置混合型证券投资基金基金经理。2023年11月 23日起担任汇添富医疗服务灵活配置混合型证券投资基金基金经理。2023年11月23日任汇添富全球医疗 保健混合型证券投资基金基金经理。现任汇添富创新医药主题混合型证券投资基金基金经理。 来源：金融界 汇添富医疗服务灵活配置混合A股票持仓前十占比合计64.17%，分别为：恒瑞医药（10.23%）、科伦药 业（9.09%）、百利天恒（8.94%）、海思科（8.27%）、信立泰（6.66%）、泽璟制药-U（6.10%）、新 诺威（4.69%）、荣 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年4月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 諾誠健華醫藥有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2025年5月7日 I. 法定/註冊股本變動 FF301 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09969 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 25,000,000,000 | USD | 0.000002 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 25,000,000,000 | USD | 0.000002 | USD | | 50,000 ...

Group 1 - In April 2025, out of 8,451 comparable mixed funds, 1,899 funds saw an increase in net value, while 6,529 funds experienced a decline, and 23 funds remained flat [1] - The top two performing funds for April were Zhonghang Youxuan Lihang Mixed Fund A and C, with returns of 17.30% and 17.25% respectively [1] - These two funds, established on December 24, 2024, have cumulative returns of 42.99% and 42.67% as of April 30, 2025 [1] Group 2 - Nine funds under Huatai Fuhua Fund Management Co., Ltd. achieved monthly returns exceeding 10%, including Huatai Fuhua North Exchange Innovation Selected Mixed Fund A and C [2] - The Huatai Fuhua Medical Service Flexible Allocation Mixed Fund A had a return of 12.18% in April and a cumulative return of 55.60% since its inception [3] - The fund manager believes the pharmaceutical industry will show strong anti-cyclical and technological attributes over the next 2 to 3 years, focusing on innovative drugs and high-barrier medical equipment [3] Group 3 - The top-performing funds in April included Huatai Fuhua Medical Service Flexible Allocation Mixed Fund A, with a scale of 4.408 billion yuan, and a cumulative net value of 1.5560 yuan [3] - The two funds, Fuguo Precision Medical Flexible Allocation Mixed Fund A and Zhongyin Innovation Medical Mixed Fund A, also performed well with returns of 11.21% and 10.57% respectively [4][5] - Fuguo Precision Medical Flexible Allocation Mixed Fund A has a cumulative return of 184.98% since its inception [4] Group 4 - A total of 59 mixed funds saw declines exceeding 10% in April, with Tianzhi Quantitative Core Selected Mixed Fund C and A at the bottom with returns of -18.19% and -18.18% respectively [5] - These funds have cumulative returns of -45.73% and -46.21% since their inception [5] - The top ten holdings of these underperforming funds included companies in the optical and semiconductor sectors [5][6]

Group 1: Energy Storage Industry - Advanced Energy is one of the three leading industries in Changping District, with a focus on innovation in energy storage solutions [1] - Zhonghai Energy is developing iron-chromium flow batteries, which have a 90% water-based electrolyte, significantly reducing fire risks associated with traditional lithium-ion batteries [1][2] - The company has secured multiple billion-level orders and expects to achieve a revenue of 200 million yuan this year, with plans to establish three production bases across the country [2] Group 2: Pharmaceutical Industry - Innovent Biologics has received approval for its new BTK inhibitor, Oubatinib, for treating chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), expanding its market potential [2][3] - The drug is also being explored for use in autoimmune diseases, with several clinical trials progressing to global Phase III [3] - The innovative design of Oubatinib allows for precise targeting of BTK proteins, minimizing side effects and enhancing safety for long-term use in autoimmune conditions [3] Group 3: Synthetic Biology and Advanced Manufacturing - The synthetic biology sector is emerging in Changping, with companies like Weiyuan Synthetic innovating in the production of rare sugars like allulose through engineered microorganisms [4] - The rapid growth of Weiyuan Synthetic is supported by public service platforms established by the district to aid startups in high-throughput screening and other essential services [4] - The private sector in Changping contributes significantly to the local economy, accounting for over 79.8% of large-scale enterprises and generating substantial tax revenue and employment [4]